- 1 A phase 1/2 randomized, double-blinded, placebo controlled ascending dose trial to assess
- 2 the safety, tolerability and immunogenicity of ARCT-021 in healthy adults
- 3
- 4 Jenny G. Low, M.R.C.P., M.P.H., Ruklanthi de Alwis, M.P.H., Ph.D., Shiwei Chen, Ph.D.,
- 5 Shirin Kalimuddin, M.R.C.P., M.P.H., Yan Shan Leong, B.Sc., Tania Ken Lin Mah, B.Sc.,
- 6 Natalene Yuen B.Sc., Hwee Cheng Tan, Summer L Zhang M.Sc., Jean X.Y. Sim, M.R.C.P,
- 7 Yvonne F.Z. Chan, M.R.C.P., Ayesa Syenina, PhD., Jia Xin Yee, B.Sc., Eugenia Z. Ong, Ph.D.,
- 8 Rose Sekulovich, Ph.D., Brian B. Sullivan, Ph.D., Kelly Lindert, M.D., Sean B. Sullivan, Ph.D.,
- 9 Pad Chivukula, Ph.D., Steven G. Hughes M.B., B.S., M.B.A., F.R.C.P., Eng Eong. Ooi, B.M.,
- 10 B.S., Ph.D.
- 11
- 12 Correspondence to:
- 13 Steven G Hughes
- 14 Arcturus Therapeutics, Inc., 10628 Science Center Drive, Suite 250, San Diego, CA92121, USA.
- 15 Email: drstevehughes@gmail.com

16 Abstract

17 Background

18 The pandemic of coronavirus disease-19 (Covid-19) continues to afflict the lives and livelihoods 19 of many as global demand for vaccine supply remains unmet.

- 20
- 21 Methods
- 22 Phase 1 of this trial (N=42) assessed the safety, tolerability and immunogenicity of ascending
- 23 levels of one-dose ARCT-021, a self-amplifying mRNA vaccine against Covid-19. Phase 2
- 24 (N=64) tested two-doses of ARCT-021 given 28 days apart. Both young and older adults were
- enrolled. The primary safety outcomes were local and systemic solicited adverse events (AEs)
- reported immediately and up to 7 days post-inoculation and unsolicited events reported up to 56
- 27 days after inoculation. Secondary and exploratory outcomes were antibody and T cell responses
- 28 to vaccination, respectively.
- 29
- 30 Results
- 31 ARCT-021 was well tolerated up to one 7.5 µg dose and two 5.0 µg doses. Local solicited AEs,
- 32 namely injection-site pain and tenderness, as well as systemic solicited AEs, such as fatigue,
- 33 headache and myalgia, were more common in ARCT-021 than placebo recipients, and in
- 34 younger than older adults. Seroconversion rate for anti-S IgG was 100% in all cohorts except for
- 35 the 1 µg one-dose in younger adults and the 7.5 µg one-dose in older adults, which were each
- 36 80%. Neutralizing antibody titers increased with increasing dose although the responses
- 37 following 5.0 µg and 7.5 µg ARCT-021 were similar. Anti-S IgG titers overlapped with those in
- 38 Covid-19 convalescent plasma. ARCT-021 also elicited T-cell responses against the S
- 39 glycoprotein.
- 40
- 41 Conclusion

Taken collectively, the favorable safety and immunogenicity profiles support further clinicaldevelopment of ARCT-021.

44

45 Introduction

46

47 The coronavirus disease 2019 (Covid-19) pandemic, caused by the severe acute respiratory 48 syndrome coronavirus-2 (SARS-CoV-2), has devastated lives globally¹. Accelerated vaccine 49 deployment has started to reverse this trend^{2,3}. The most effective vaccines have been mRNA vaccines⁴⁻⁶. A newer synthetic mRNA platform - self-amplifying RNA (sa-mRNA) - may have an 50 51 added advantage^{7,8}; *in situ* mRNA amplification may allow for smaller doses to be administered, stretching the reach of limited vaccine supply to greater number of people⁹. However, there 52 53 remains a paucity of data that informs on the safety and immunogenicity of such a vaccine 54 construct.

55

56 We conducted a first-in-human clinical trial in healthy adults to evaluate the safety, tolerability 57 and immunogenicity of ARCT-021, a self-transcribing and replicating mRNA (STARRTM) 58 vaccine candidate for the prevention of Covid-19. The mRNA is a replicon that comprises the 59 Venezuelan equine encephalitis virus (VEEV) genome in which the structural genes have been 60 replaced with the SARS-CoV-2 full-length spike (S) gene, and formulated with the proprietary 61 LUNAR[®] lipid nanoparticle (LNP). Translation of the replicon produces a multi-protein replicase 62 complex that amplifies a subgenomic mRNA for elevated expression of the S glycoprotein. 63 Preclinical experiments showed that a single dose of ARCT-021 elicited strong Th1-predominant 64 humoral and cellular immune responses against the S protein that protected K-18 human ACE2 transgenic mice from lethal SARS-CoV-2 challenge¹⁰. Here we report the findings from the Phase 65 66 1/2 clinical trial.

67

68 Methods

69

70 Trial design, participants and oversight

ARCT-021-01 is a randomized, double-blinded, placebo (0.9% saline) controlled study to assess the safety, tolerability and immunogenicity of different dose levels of ARCT-021. The primary endpoint was safety and tolerability; secondary and exploratory endpoints were antibody and Tcell responses. The trial was conducted at the Singapore Health Services (SingHealth) Investigational Medicine Unit, following approvals by the SingHealth Centralized Institutional

Review Board (CIRB F/2020/2553) and the Singapore Health Sciences Authority. The trial was
registered in clinicaltrial.gov (NCT04480957). A safety review committee reviewed data
regarding safety and overall trial progress, including dose escalation decisions.

79

80 The trial comprised two overlapping parts and evaluated a range of doses of ARCT-021 versus 81 placebo given as one- or two-dose administration to younger (21 to 55 years) and older (56 to 80 82 years) adult participants. In the Phase 1 part, a one-dose administration (dose levels 1.0 µg, 5.0 µg, 83 7.5 µg and 10 µg ARCT-021 versus placebo) was given as an intramuscular (IM) injection to younger adults (Cohorts A, B, D1 and C, respectively) and a single dose (7.5 µg ARCT-021 versus 84 85 placebo) was given to older adults (Cohort D2). In the Phase 2 part, two-dose administrations of 86 3.0 µg and 5.0 µg ARCT-021 versus placebo separated by 28 days were administered to younger 87 participants (Cohorts F and E) and older participants (Cohorts H and G), respectively. All 88 participants were followed up for 56 days after the last study vaccine administration.

89

Full lists of the inclusion and exclusion criteria are provided in the protocol. Written informedconsent was provided by all the participants before enrollment.

92

Arcturus Therapeutics, Inc. was the regulatory sponsor of the trial. Both Arcturus Therapeutics and Duke-NUS Medical School co-designed the clinical trial and were responsible for the collection, analysis, and interpretation of the data and for the writing of the report. Arcturus Therapeutics and the corresponding author had full access to all the data in the trial and had final responsibility for the decision to submit the manuscript for publication. All the trial data were available to all the authors. Clinical monitoring, pharmacovigilance, and data management were performed by the Contract Research Organization, CTI.

100

101 <u>Trial procedures</u>

Participants were randomized after completing all screening assessments and eligibility criteria. Phase 1 participants were randomized 5:2 to receive ARCT-021 or placebo. Phase 2 participants were randomized 3:1 to receive ARCT-021 or placebo. All participants were administered 0.5-ml injections of ARCT-021 or placebo into the lateral aspect of the deltoid muscle of the nondominant arm while the second injection (Phase 2 cohorts) was administered into the contralateral

arm. All participants were observed for a minimum of 4 hours after the injection. Blood samples
 were obtained for safety and immunogenicity assessments according to protocol schedule. The

initial planned single doses to be tested were 1.0 μ g, 5.0 μ g, 10 μ g and 20 μ g in the single dose

110 cohorts; The final tested doses were 1.0 μ g, 5.0 μ g, 7.5 μ g and 10 μ g in the single dose cohorts and

- 111 3.0ug and 5.0ug in the two dose cohorts.
- 112

113 Vaccine and placebo

114 ARCT-021 was presented as a sterile, frozen, aqueous formulation with 0.2 mg/mL of mRNA-

115 2002 and as a 1.0 mL fill (0.2 mg/1 mL) in 2-mL Type I glass vials, stored frozen at -70°C (+/-

116 10°C). It is a white to off-white liquid when thawed with a nominal pH of 8.0 and osmolality of

approximately1300 mOsm/kg. The placebo was 0.9% sterile saline provided by the study center.

118

119 Safety Assessments

Local and systemic solicited and unsolicited AEs were recorded daily by the participant in a symptom diary for at least 7 days and up to 14 days post vaccination if any events persisted beyond Day 7. The symptom diaries were reviewed by site staff at study visits for up to 14 days post each injection. Injection site was inspected at all visits up to Day 15 (for first injection)/Day 43 (for second injection) or until resolution of local reactogenic event(s). Unsolicited events were collected at all visits and for the duration of study participation.

126

127 <u>Immunogenicity</u>

128 IgM, IgA and IgG against full-length recombinant S protein were assessed using a Luminex 129 immuno-assay. IgG against the S protein subdomains (RBD, NTD and S2) were also measured for 130 5.0 µg, 7.5 µg single and 5.0 µg expansion cohorts. Neutralizing antibody was measured using 131 plaque reduction neutralization test (PRNT), with a clinical SARS CoV-2 isolate (hCoV-19/Singapore/2/2020), and the serum titer that neutralizes 50% of the virus inoculum (PRNT₅₀) 132 133 was calculated as previously described¹¹. SARS-CoV-2 specific T-cell responses were assessed 134 using flow cytometry (FC) and IFNy ELISPOT assay following stimulation with overlapping S 135 protein peptide pools.

136

137 <u>Statistical Analysis</u>

138 No formal sample size calculation was performed. Based on experience from previous studies with 139 other RNA based therapies, the chosen cohort sizes were considered sufficient to meet the 140 objectives of the study while minimizing unnecessary participant exposure. For analysis of safety 141 and humoral immunogenicity, placebo participants were pooled by age group and number of doses 142 administered as follows: A to D1 pooled, E and F pooled, G and H pooled. D2 was the only single 143 dose older adult cohort so D2 placebos were not pooled. For humoral immunogenicity, confidence 144 intervals of the geometric means were calculated with the Student's t distribution on log-145 transformed data. Seroconversion was defined as at least a 4-fold increase in antibody titer from 146 baseline.

147

148 **Results**

149 <u>Trial Participants</u>

In total, 169 healthy volunteers were screened, with 106 participants randomized and injected. The distribution of participants by cohort is shown in Figure 1. All participants received assigned doses of ARCT-021. All enrolled participants completed the planned study scheduled trial visits. A summary of demographic characteristics by treatment assignment is presented in Table 1.

154

155 <u>Safety</u>

156 A summary of solicited local and systemic adverse events (AE) is presented in Figures 2 and 3. 157 ARCT-021 was generally well tolerated up to the 7.5 µg dose. The 10 µg dose was associated with 158 more local and systemic solicited AE, including grade 3 severity. Although the study stopping 159 rules were not met, the protocol was amended to remove further dose escalation. A younger 160 (Cohort D1) and older adult (Cohort D2) one-dose cohorts at the 7.5 µg dose level were added 161 following safety review. A single serious adverse event due to cellulitis of the foot in a placebo 162 recipient following an insect-bite was reported. It was medically attended and resolved after two 163 days. All participants in the 2-dose cohorts completed the vaccinations without any delay.

164

165 Solicited Treatment Emergent Adverse Events

166 Local reactions

167 Sixty-nine (88.5%) participants who received ARCT-021 reported local solicited AEs, as 168 compared to 21.4% of placebo-treated participants (Figure 2). These included injection site

169 tenderness and pain in 73.1% and 60.3% of participants, respectively. In the two-dose younger 170 adult cohorts, local solicited AE occurred in 11(91.7%) following the first dose at both 5.0 µg and 171 3.0 µg and in 11 (91.7%) and 12 (100%), respectively, following the second dose. In older adults, 172 local solicited events occurred in 8 (66.7%) and 9 (75%) following the first dose and in 8 (66.7%) 173 and 10 (83.3%) following the second dose in the 5.0 µg and 3.0 µg dose cohorts, respectively. A 174 higher proportion of participants experienced moderate grade injection site tenderness with the 175 second dose. At the same dose level, a higher proportion of younger than older adults experienced 176 \geq grade 2 solicited AE. There was no reported injection site erythema or swelling. There was one 177 grade 3 injection site pain at the 10µg dose. There were no grade 4 local reactions and no 178 discernable dose relationship.

179

180 Systemic Reactions

181 Overall, 62.8% of participants who received ARCT-021 reported a systemic solicited AE as 182 compared to 46.4% amongst the placebo recipients (Figure 3). The most common events were 183 fatigue (50.0%), headache (34.6%), myalgia (28.2%), chills (25.6%), and fever (14.1%) and were 184 more common in younger than older adults. Systemic AEs were primarily mild or moderate with 185 no grade 4 events reported. Grade 3 solicited events occurred primarily in the 10 µg dose cohort. 186 Two grade 3 events (fatigue and arthralgia) occurred in a single participant following the second 187 dose in the 5.0 µg older adult cohort. Severity of systemic AEs trended with dose. Most systemic 188 AEs commenced within 1 to 2 days after vaccination and resolved or reduced in severity within 7 189 days.

190

191 Unsolicited Systemic Treatment Emergent Adverse Events

Unsolicited AEs are summarized in Supplementary Table 1. In general, more participants vaccinated with ARCT-021 reported unsolicited AEs after vaccination. Five were severe, occurring primarily in the 10 µg dose cohort. These events occurred on the day after injection and resolved or improved in severity within 2 days after onset. One participant in older adult 3.0 µg two dose cohort (F) experienced grade 3 transaminitis 57 days after the last dose of ARCT-021. This event was classed as unlikely related by the Investigator and resolved after 18 days. No severe events occurred in placebo treated participants.

199

200 Abnormal hematological and biochemical findings

201 There appeared to be a dose-related trend for >grade 2 lymphopenia with 0%, 25%, 26.5%, 30.0% 202 and 40.0% of participants affected at the 1.0 µg, 3.0 µg, 5.0 µg, 7.5 µg and 10 µg dose levels, 203 respectively. Onset of lymphopenia occurred within 24 hours after injection and resolved 204 uneventfully, generally within a day. The incidence was similar following the first (14 of 78 205 participants [17.9%]) and second dose (10 of 48 participants [20.8%]). Three of 48 (6.3%) 206 participants had \geq grade 2 lymphopenia following both the first and second injection. There was 207 no trend for increased severity following the second injection. The incidence was similar in older 208 (24.1%) and younger adults (26.5%). There were 10 (12.8%) Grade 2 neutropenia events, the 209 incidence of which was higher in older (17.2%) than younger (10.2%) adults. All neutropenic 210 episodes were asymptomatic, resolved spontaneously and did not result in any sequelae.

211

Post-baseline elevations of ALT occurred in 5 ARCT-021 treated participants (Supplementary
Table 3). Two of these participants had ALT elevation at screening, which had normalized at Day
No elevations of hepatic enzymes were observed in placebo participants. There were no other
notable laboratory abnormalities.

216

217 <u>Immunogenicity</u>

218

219 SARS-CoV-2 Binding Antibodies and Neutralization Response

220 Seroconversion rate for anti-S IgG was 100% in all cohorts except for the one-dose younger adult 221 cohort A (1µg) and the one-dose older adult cohort D2 (7.5 µg), which were both 80%. The IgG 222 response increased with increasing dose (Fig 4A, Table S5 and S6), although there was a trend for 223 better responses at the 5.0 µg dose than at the 7.5 µg dose in older adults after a single dose 224 (compared at Day 29 in the two-dose cohorts). With the exception of the 1 µg dose, S-binding IgG 225 titers overlapped with the range of antibodies in Covid-19 convalescent plasma (Fig. 4A). Vaccine-226 induced IgG antibodies bound the various S protein subdomains, including the RBD, NTD and the 227 highly conserved S2 (Fig. 4B). PRNT₅₀ titers increased with increasing dose, while the responses 228 were similar following one-dose of 5.0 μ g and 7.5 μ g. At doses \ge 3 μ g, PRNT₅₀ titers were within 229 the range observed in convalescent sera from patients with mild to moderate Covid-19¹⁰. 230

8

231 SARS-CoV-2 T-Cell Response

232 T-cell responses were observed on both ELISPOT and ICS in response to stimulation with six 233 peptide pools covering the entire S glycoprotein (Fig. S1). IFNy ELISPOT responses were 234 generally maximal at Day 15, and were similar at the 5.0 µg and 7.5 µg dose in younger adults 235 (Fig. 4D-E and Fig. S2). Responses in the 5.0 µg older adult cohort peaked after the second dose 236 (Fig. 4E and Fig. S3). IFNy ELISPOT responses were generally higher in younger adults (Fig. 4D-237 E). CD4 T-cell IFN-γ responses as measured by ICS showed the greatest values at Day 29 in the 238 1.0 µg and 5.0 µg single dose cohorts (Fig. S5). CD4 T-cell IFN-y responses were generally greater 239 in older adults than younger adults at the 5.0 μ g and 7.5 μ g doses and were similar between the 240 two age groups at the 3 μ g dose. A further increase in CD4 T-Cell IFN- γ responses following 241 second dose was only seen in the 5.0 µg younger adults. At all tested doses, the CD4 T-cell 242 responses were Th1 dominant (Fig. S6). The CD8 T-cell IFN-y cytokine responses by ICS showed 243 the highest values at Day 29 in the 5.0 μ g single dose cohort. CD8 IFN- γ responses in the older adult cohorts were higher than the responses observed in the younger adult cohorts at the same 244 245 dose (Fig. S4). There was no further increase in CD8 T-cell IFN-y responses following the second 246 dose (Fig. S4).

247

248 Discussion

249

250 The shortage in Covid-19 vaccine supply continues to affect global recovery from this pandemic.

251 A dose-sparing sa-mRNA vaccine could thus contribute to addressing this shortage.

252

We found an overall favorable safety profile up to 7.5ug dose. Over 96% of all AEs were either mild or moderate. Transient lymphopenia and neutropenia, possibly due to innate immune driven redistribution of lymphocytes¹² were observed, similar to other mRNA vaccines^{13,14}.

256

ARCT-021 is also immunogenic. Anti-S IgG antibody levels were within the range of convalescent plasma, even after just one-dose. Vaccination also produced anti-S antibody of different types – IgM and IgA – in addition to IgG. These antibodies can elicit Fc-mediated functions, such as complement activation, antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis, as well as protect the mucosa. Indeed, recent reports suggest that Covid-19 can be prevented despite

low levels¹⁵ or even absence of neutralizing antibodies¹⁶. Even antibodies that enhance SARSCoV-2 infection *in vitro* protected non-human primates (NHPs) against SARS-CoV-2 challenge¹⁷.
Finally, onset of mRNA vaccine-mediated protection against Covid-19 was associated with the
development of anti-S antibodies that showed ADCC activity, along with S-reactive T cells,
without neutralizing antibodies^{11,18}. These findings collectively indicate that other functions of
antibodies besides virus neutralization play key roles in protecting against Covid-19.

268

Although a single dose of ARCT-021 was immunogenic, the second dose did not boost antibody titers dramatically. This may be due to three reasons: Firstly, the one-month interval between prime and boost may be too short for maximal boosting; secondly, we have not modified the S gene based on the immunogenicity and efficacy observed in our preclinical study¹⁰ and; finally, we wanted to ensure that our CD8 T cell response would be directed against the native S since, at the time when ARCT-021 development began, the CD8 T cell epitopes had not been fully mapped.

275

276 Our intention to elicit appreciable CD8 T cell responses with vaccination was driven by the 277 collective body of evidence indicating the importance of cellular immunity in preventing Covid-278 19. Pre-clinical studies on ARCT-021 showed that vaccine-induced protection against SARS-279 CoV-2 was mediated primarily by CD8 T-cells rather than B cells¹⁰. In NHPs, cellular immunity compensated for low antibody levels in protecting against SARS-CoV-2 infection¹⁹. Clinically, 280 281 delayed T but not B cell responses were associated with severe disease²⁰. Recognition of epitopes 282 spanning the S protein by CD8 T cells could also protect against neutralizing antibody-evading variants of concern (VOC)²¹; several such VOCs are presently spreading globally and will be the 283 main challenge for any new Covid-19 vaccines²². Indeed, T cell responses may underpin the 284 285 sustained efficacy of mRNA vaccines against these VOCs²³.

286

Our findings contrast with the phase 1 trial finding of another sa-mRNA vaccine²⁴. The reasons for the different outcomes are uncertain currently although there are differences in both the S gene sequence and vaccine formulation^{10,25}. Further investigations to understand the underpinnings of different immunogenicity outcome could be informative on future sa-mRNA vaccine design.

291

10

- 292 Taken collectively, the favorable safety and immunogenicity profiles support further clinical
- development of ARCT-021. A larger multi-center phase 2 clinical trial (NCT04668339) recruiting
- 294 ~600 healthy adult volunteers is ongoing to guide a subsequent phase 3 clinical trial.
- 295

Author affiliations

- 297 From Singapore General Hospital (JGL, SK, JXYS, YFZC); Duke-National University of
- 298 Singapore Medical School (JGL, RdA, SC, SK, YSL, TKLM, NY, HCT, SLZ, AS, JXY, EZO,
- EEO); Nanyang Technological University (NY); Arcturus Therapeutics (RS, BBS, KL, SBS, PC,
- 300 SGH).
- 301
- 302 **References**
- Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020 (In eng). DOI: 10.1016/S0140-6736(20)30185-9.
- Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide
 Mass Vaccination Setting. N Engl J Med 2021;384(15):1412-1423. DOI:
 10.1056/NEJMoa2101765.
- Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19
 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective
 cohort study. Lancet 2021;397(10285):1646-1657. DOI: 10.1016/S0140-6736(21)00677 2.
- Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther 2020. DOI: 10.1038/s41434-020-00204-y.
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARSCoV-2 Vaccine. N Engl J Med 2021;384(5):403-416. DOI: 10.1056/NEJMoa2035389.
- 3166.Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA317Covid-19Vaccine.NEnglJMed2020;383(27):2603-2615.DOI:31810.1056/NEJMoa2034577.
- 319 7. Lundstrom K. Self-Replicating RNA Viruses for RNA Therapeutics. Molecules
 320 2018;23(12). DOI: 10.3390/molecules23123310.
- Tews BA, Meyers G. Self-Replicating RNA. Methods Mol Biol 2017;1499:15-35. DOI: 10.1007/978-1-4939-6481-9_2.
- 323 9. Castillo JC, Ahuja A, Athey S, et al. Market design to accelerate COVID-19 vaccine
 324 supply. Science 2021;371(6534):1107-1109. (In eng). DOI: 10.1126/science.abg0889.
- de Alwis R, Gan ES, Chen S, et al. A single dose of self-transcribing and replicating RNA based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. Mol Ther
 2021 (In eng). DOI: 10.1016/j.ymthe.2021.04.001.
- Kalimuddin S, Tham CY, Qui M, et al. Early T cell and binding antibody responses are associated with Covid-19 RNA vaccine efficacy onset. Med (N Y) 2021 (In eng). DOI: 10.1016/j.medj.2021.04.003.

- Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. Type I interferons directly regulate
 lymphocyte recirculation and cause transient blood lymphopenia. Blood
 2006;108(10):3253-61. DOI: 10.1182/blood-2006-06-027599.
- Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of COVID-19 RNA vaccine
 BNT162b1 in adults. Nature 2020;586(7830):589-593. DOI: 10.1038/s41586-020-2639-4.
- 336 14. Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human
 337 antibody and TH1 T cell responses. Nature 2020;586(7830):594-599. DOI:
 338 10.1038/s41586-020-2814-7.
- Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive
 of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021 (In eng).
 DOI: 10.1038/s41591-021-01377-8.
- 342 16. Soresina A, Moratto D, Chiarini M, et al. Two X-linked agammaglobulinemia patients
 343 develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol
 344 2020;31(5):565-569. (In eng). DOI: 10.1111/pai.13263.
- Li D, Edwards RJ, Manne K, et al. The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates. bioRxiv 2021 (In eng). DOI: 10.1101/2020.12.31.424729.
- Tauzin A, Nayrac M, Benlarbi M, et al. A single BNT162b2 mRNA dose elicits antibodies
 with Fc-mediated effector functions and boost pre-existing humoral and T cell responses.
 bioRxiv 2021 (In eng). DOI: 10.1101/2021.03.18.435972.
- McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 2021;590(7847):630-634. (In eng). DOI: 10.1038/s41586-020-03041-6.
- Tan AT, Linster M, Tan CW, et al. Early induction of functional SARS-CoV-2-specific T
 cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep
 2021;34(6):108728. (In eng). DOI: 10.1016/j.celrep.2021.108728.
- 357 21. Geers D, Shamier MC, Bogers S, et al. SARS-CoV-2 variants of concern partially escape
 358 humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. Sci
 359 Immunol 2021;6(59) (In eng). DOI: 10.1126/sciimmunol.abj1750.
- 360 22. Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape
 361 neutralization by vaccine-induced humoral immunity. Cell 2021;184(9):2523. (In eng).
 362 DOI: 10.1016/j.cell.2021.04.006.
- Andreano E, Rappuoli R. SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies. Nat Med 2021;27(5):759-761. (In eng). DOI: 10.1038/s41591-021-01347-0.
- Pollock KM, Cheeseman HM, Szubert AJ, et al. Safety and immunogenicity of a selfamplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.
 2021;PREPRINT.
- 369 25. McKay PF, Hu K, Blakney AK, et al. Self-amplifying RNA SARS-CoV-2 lipid
 370 nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat
 371 Commun 2020;11(1):3523. (In eng). DOI: 10.1038/s41467-020-17409-9.
- 372

Cohort			Sin	gle Dose	Cohorts		Two-Dose Cohorts						
			Age 21 -	55		Age	56 - 80		Age 21 - 5	5		Age 56 - 8	80
					Pooled					Pooled			Pooled
	Cohort	Cohort	Cohort	Cohort	Placebo	Cohort	Cohort	Cohort	Cohort	Placebo	Cohort	Cohort	Placebo
	Α	В	С	D1	Cohorts	D2	D2	Е	F	Cohorts	G	Н	Cohorts
Variable	1µg	5µg	10µg	7.5µg	A to D1	7.5µg	Placebo	5μg	Зµg	E and F	5µg	3µg	G and H
Number of Participants	5	10	5	5	10	5	2	12	12	8	12	12	8
Sex - n (%)													
Male	3	6	2	4	8	5	1	8	10	5	11	8	7
	(60.0)	(60.0)	(40.0)	(80.0)	(20.0)	(100)	(50.0)	(66.7)	(83.3)	(62.5)	(91.7)	(66.7)	(87.5)
Female	2	4	3	1	2	0	1	4	2	3	1	4	1
	(40.0)	(40.0)	(60.0)	(20.0)	(20.0)	(0)	(50.0)	(33.3)	(16.7)	(37.5)	(8.3)	(33.3)	(12.5)
Race - n (%)†													
Asian	5	10	5	4	10	5	2	11	10	7	12	12	7
	(100)	(100)	(100)	(80.0)	(100)	(100)	(100)	(91.7)	(83.3)	(87.5)	(100)	(100)	(87.5)
White	0	0	0	1	0	0	0	0	1	1	0	0	1
	(0)	(0)	(0)	(20.0)	(0)	(0)	(0)	(0)	(8.3)	(12.5)	(0)	(0)	(12.5)
American Indian or Alaskan	0	0	0	0	0	0	0	1	0	0	0	0	0
Native	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(8.3)	(0)	(0)	(0)	(0)	(0)
Other	0	0	0	0	0	0	0	0	1	0	0	0	0
	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(8.3)	(0)	(0)	(0)	(0)
Hispanic Ethnic Group – n (%)†	0	0	0	0	0	0	0	0	0	0	0	0	0
	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
Age (years) ‡													
Mean (SD)	35	39.5	41.4	40.4	33.5	64	61.5	34.5	38	39.1	62.3	61.7	63.3
	(±9.17)	(±7.15)	(±12.48)	(±10.41)	(±8.72)	(±5.61)	(±6.36)	(±8.33)	(±9.34)	(±7.95)	(±4.63)	(±3.77)	(±5.70)

Table 1._Demographic Characteristics of the Participants, According to Dose Cohort and Age Group*

Cohort			Sin	gle Dose	Cohorts			Two-Dose Cohorts						
			Age 21 -	55		Age	56 - 80		Age 21 - 5	5		Age 56 - 8	80	
					Pooled					Pooled			Pooled	
	Cohort	Cohort	rt Cohort C	Cohort	Placebo	Cohort	Cohort	Cohort	Cohort	Placebo	Cohort	Cohort	Placebo	
	Α	В		D1	Cohorts	D2	D2	Е	F	Cohorts	G	Н	Cohorts	
Variable	1µg	5µg	10µg	7.5µg	A to D1	7.5µg	Placebo	5µg	3µg	E and F	5µg	3μg	G and H	
Median [range]	32.0	40.0	44.0	47.0	34.5	64.0	61.5	35.5	35.0	37.0	62.0	61.5	64.5	
	[28-50] [29-51] [24-55] [24-48]				[21-46]	[57-70]	[57-66]	[21-47]	7] [22-51] [30-51]		[56-70]	[56-68]	[56-71]	

Abbreviations: N = total number of subjects in each dose cohort; n = number of subjects contributing to the summary; SD = standard deviation

*Percentages may not total 100 because of rounding

[†]Race and ethnic group were reported by the participant.

‡ The age of the participants was the age at the time of screening



Figure 1. Enrolment and randomization of trial participants.

Abbreviations: N = number of participants in the cohort; n = number of participants in each treatment group;

OA = older adults (56-80 years); YA = younger adults (21-55 years).

Phase 1 - Single injection, escalating dose. Study duration 56 days post first injection.

Phase 2 - Two same dose injections, 28 days apart. Study duration 85 days post first injection.



Figure 2. Local solicited adverse events. Shown are the percentages of vaccinated participants reporting local solicited events. Data are represented for age groups, 21-55 years (Panel A) and 56-80 years (Panel B). Severity of local solicited Events are displayed as mild (green), moderate

(blue), severe (orange) or life-threatening (red). *Note, injection site swelling and injection site redness were not reported. YA=Younger Adults (21-55); OA=Older Adults (56-80).



Figure 3. Systemic solicited adverse events. Percentage of systemic solicited events reported in vaccinated participants aged 21-55 years (Panel A) and 56-80 years (Panel B). Severity of systemic solicited Events are displayed as mild (green), moderate (blue), severe (orange) or life-threatening (red). YA=Younger Adults (21-55); OA=Older Adults (56-80).



Figure 4. Antibody and T cell responses. Shown are IgG reciprocal endpoint titers to SARS-CoV-2 whole ectodomain Spike using Luminex immune-Assay (Panel A). IgG reciprocal titers to the Spike sub-domains, i.e. receptor-binding domain (RBD), N-terminal binding domain (NTD) and domain 2 (S2) using Luminex immuno-assay is represented for selected cohorts and timepoints (Panel B). Antibody neutralization of live SARS-CoV-2 virus was measured using a BSL3 plaque reduction neutralization assay (PRNT) and represented as 50% neutralization titers (PRNT50) (Panel C). Cellular immunity and T cell responses in prime and prime-boost cohorts were measured using an interferon gamma (IFN γ) enzyme-linked immune absorbent spot (ELISPOT) assay and represented as spot-forming cells (SFC) per million PBMCs (Panel D and

E). Displayed ELISPOT results are cumulative responses of six peptide pools spanning the entire SARS-CoV-2 Spike. Peptide pool-specific responses presented in Fig. S2 and S3. For Panels A-C, the error bars display standard deviation around the GMT depicted by a horizontal bar. For Panels D and E, the whiskers display standard deviation (SD) around the mean (horizontal bar). Each dot represents an individual participant.

Supplementary Appendix

Table S1: Summary of Unsolicited Treatment Emergent Adverse Events According to Dose Cohort and Age Group

Cohort				Single Dos	e		Two-Dose						
			Age 21 - 5	5		Age 5	56 - 80		Age 21 - 55	;		Age 56 - 80)
					Pooled					Pooled			Pooled
					Placebo					Placebo			Placebo
	Cohort A	Cohort B	Cohort C	Cohort D1	Cohorts	Cohort D2	Cohort D2	Cohort E	Cohort F	Cohorts	Cohort G	Cohort H	Cohorts
	1µg	5μg	10µg	7.5µg	A to D1	7.5µg	Placebo	5µg	3μg	E and F	5μg	3μg	G and H
Event Category / n(%)	(N=5)	(N=10)	(N=5)	(N=5)	(N=10)	(N=5)	(N=2)	(N=12)	(N=12)	(N=8)	(N=12)	(N=12)	(N=8)
Any Unsolicited Event	4 (80.0)	7 (70.0)	5 (100.0)	4 (80.0)	5 (50.0)	5 (100.0)	0	8 (66.7)	8 (66.7)	6 (75.0)	12 (100.0)	8 (66.7)	3 (37.5)
Related	4 (80.0)	6 (60.0)	5 (100.0)	3 (60.0)	0	5 (100.0)	0	7 (58.3%)	8 (66.7%)	1 (12.5%)	9 (75.0%)	5 (41.7%)	1 (12.5%)
Severe	0	0	2 (40.0)	0	0	0	0	0	0	0	0	1 (8.3)	0
Life threatening	0	0	0	0	0	0	0	0	0	0	0	0	0
Any Serious Unsolicited Event	0	0	0	0	1 (10.0)	0	0	0	0	0	0	0	0
Related	0	0	0	0	0	0	0	0	0	0	0	0	0
Severe	0	0	0	0	0	0	0	0	0	0	0	0	0
Life-threatening	0	0	0	0	0	0	0	0	0	0	0	0	0
Any Unsolicited Event Leading to	0	0	0	0	0	0	0	0	0	0	0	0	0
Withdrawal													
Related	0	0	0	0	0	0	0	0	0	0	0	0	0
Severe	0	0	0	0	0	0	0	0	0	0	0	0	0
Life-threatening	0	0	0	0	0	0	0	0	0	0	0	0	0
Death	0	0	0	0	0	0	0	0	0	0	0	0	0

Table S2: Medically Attended Events by Dose Cohort and Age Group

Cohort				Single Dos	e			Two-Dose						
			Age 21 - 5	5		Age 5	6 - 80		Age 21 - 55	;		Age 56 - 80)	
					Pooled					Pooled			Pooled	
					Placebo					Placebo			Placebo	
	Cohort A	Cohort B	Cohort C	Cohort D1	Cohorts	Cohort D2	Cohort D2	Cohort E	Cohort F	Cohorts	Cohort G	Cohort H	Cohorts	
	1µg	5µg	10µg	7.5µg	A to D1	7.5µg	Placebo	5µg	3µg	E and F 5µg		3μg	G and H	
Event Term / n(%)	(N=5) (N=10) (N=5) (N=5) (N=5)				(N=10)	(N=5)	(N=2)	(N=12)	(N=12)	(N=8)	(N=12)	(N=12)	(N=8)	
Cellulitis	0	0	0	0	1 (10.0)	0	0	0	0	0	0	0	0	
Skin laceration	0	0	0	0	0	0	0	0	1 (8.3)	0	0	0	0	
Fever	0	0	0	0	0	0	0	0	0	1 (12.5)	0	0	0	
Fatigue	0	0	0	0	0	0	0	0	0	1 (12.5)	0	0	0	
Diarrhoea	0	0	0	0	0	0	0	0	0	1 (12.5)	0	0	0	
Vomiting	0	0	0	0	0	0	0	0	0	0	1 (8.3)	0	0	
Nausea	0	0	0	0	0	0	0	0	0	0	0	1 (8.3)	0	
Dizziness	0	0	0	0	0	0	0	0	0	0	1 (8.3)	1 (8.3)	0	

				ALT		
			Post V	Vaccina	tion	
		Normal	G1	G2	G3	G4
	Normal	72 (92.3)	4 (5.1)	0	1 (1.3)	0
	G1	0	1 (1.3)	0	0	0
0	G2	0	0	0	0	0
selin	G3	0	0	0	0	0
Bas	G4	0	0	0	0	0

AST													
	Pos	st Vaccinat	tion										
Normal	G1	G2	G3	G4									
75 (96.2)	2 (2.6)	1 (1.3)	0	0									
0	0	0	0	0									
0	0	0	0	0									
0	0	0	0	0									
0	0	0	0	0									

Table S3: Grade Shifts in Alanine Transaminase and Aspartate Transaminase in ARCT-021 Treated Parti	cipants
---	---------

	Number (%) of Events by Type and Severity											
		ARCT	-021-01			Pl	acebo					
	Grade 1/	Grade 2/	Grade 3 /	Total	Grade 1 /	Grade 2/	Grade 3/	Total				
Event Category	Mild	Moderate	Severe	Total	Mild	Moderate	Severe	i otar				
Any Event	387 (78.2)	91 (18.4)	17 (3.4)	495 (100.0)	66 (88.0)	9 (12.0)	0	75 (100.0)				
Any Local Solicited Event	142 (28.7)	16 (3.2)	1 (0.2)	159 (32.1)	9 (12.0)	0	0	9 (12.0)				
Any Systemic Solicited Event	152 (30.7)	28 (5.7)	11 (2.2)	191 (38.6)	31 (41.3)	4 (5.3)	0	35 (46.7)				
Any Unsolicited Adverse Event	93 (18.8)	47 (9.5)	5 (1.0)	145 (29.3)	26 (34.7)	5 (6.7)	0	31 (41.3)				

Table S4: Total Number (%) of Events by Class of Event, Treatment Group and Severity – Safety Population

Table S5. Antibody responses in 1-Dose Cohorts

					A	Age 21 – 55						Age 50	5 – 8	0
		1 µg		5 µg		7.5 μg	-	10.0 µg	Poo	led Placebo		7.5 μg	Cohort D2	
	(C	ohort A)	(0	Cohort B)	(C	ohort D1)	(C	ohort C)	(Co	horts A, B,	(C	ohort D2)]	Placebo
		N=5		N=10		N=5		N=5		C, D1)		N=5		N=2
										N=10				
Test/Time point	n	GMT	No	GMT	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT
		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)
Luminex anti-S													2	
IgG														
Day 1	5	274.0	10	166.3	5	207.5	5	511.7	10	223.7	5	141.0	2	287.0
		(111.06,		(86.17,		(178.89,		(61.69,		(126.60,		(81.90,		(NA)
		676.22)		321.01)		240.80)		4244.31)		395.45)		242.68)		
Day 8	5	364.9	10	277.1	5	221.0	5	995.4	10	278.1	5	201.6	2	398.1
		(151.09,		(163.72,		(145.26,		(54.55,		(171.81,		(117.94,		(NA)
		881.32)		468.84)		336.15)		18164.73)		450.11)		344.69)		
Day 15	5	757.8	10	2217.8	5	3698.4	5	9482.5	10	267.1	5	601.4	2	408.2
		(271.89,		(888.14,		(2628.51,		(787.96,		(162.13,		(135.44,		(NA)
		2112.02)		5538.12)		5203.68)		114114.7)		440.09)		2670.21)		
Day 29	5	2130.0	10	4781.1	5	13675.7	5	32748.6	10	236.5	5	2333.3	2	392.7
		(516.21,		(2121.61,		(6209.51,		(4963.84,		(133.33,		(265.53,		(NA)
		8788.98)		10774.20)		30119.08)		216057.2)		419.49)		20502.83)		

	Age 21 – 55											Age 5	0	
		1 µg		5 µg		7.5 μg	-	10.0 µg	Poo	led Placebo		7.5 μg	C	ohort D2
	(C	ohort A)	(C	cohort B)	(C	ohort D1)	(C	cohort C)	(Co	horts A, B,	(C	ohort D2)]	Placebo
		N=5		N=10		N=5		N=5		C, D1)		N=5		N=2
										N=10				
Test/Time point	n	GMT	No	GMT	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT
		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)
Day 36	5	2542.6	10	4189.3	5	14898.7	5	26403.5	10	289.4	5	2119.5	2	330.5
		(585.27,		(2212.27,		(5117.38,		(5567.92,		(175.29,		(252.79,		(NA)
		11046.15)		7933.24)		43375.93)		125207.5)		477.68)		17770.67)		
Day 43	5	2804.2	10	4958.6	5	15480.5	5	28763.3	10	298.2	5	2942.3	2	528.8
		(680.03,		(2484.11,		(6111.05,		(4965.70,		(171.99,		(477.76,		(NA)
		11563.45)		9898.07)		39215.12)		166608.3)		517.04)		18120.22)		
Day 56	5	2734.4	10	3843.1	5	13573.3	5	21768.1	10	297.2	5	2490.5	2	415.0
		(616.36,		(1912.88,		(4462.61,		(3916.06,		(151.31,		(318.10,		(NA)
		12130.49)		7721.23)		41284.14)		121002.1)		583.74)		19498.39)		
Live Virus														
PRNT ₅₀														
Day 1	5	20.0	10	20.0	5	20.0	5	20.0	10	20.0	5	20.0	2	20.0
		(20.00,		(20.00,		(20.00,		(20.00,		(20.00,		(20.00,		(NA)
		20.00)		20.00)		20.00)		20.00)		20.00)		20.00)		

	Age 21 – 55											Age 50	6 – 8	- 80	
		1 µg		5 µg		7.5 μg	-	10.0 µg	Poo	led Placebo		7.5 μg	С	ohort D2	
	(C	ohort A)	(C	Cohort B)	(C	ohort D1)	(C	Cohort C)	(Co	horts A, B,	(C	ohort D2)]	Placebo	
		N=5		N=10		N=5		N=5		C, D1)		N=5		N=2	
										N=10					
Test/Time point	n	GMT	No	GMT	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT	
		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)	
Day 29	5	20.0	10	24.2	5	27.7	5	32.9	10	20.9	5	24.0	2	20.0	
		(20.00,		(19.50,		(11.21,		(14.73,		(19.19,		(18.61,		(NA)	
		20.00)		29.95)		68.46)		73.56)		22.68)		30.89)			
Day 57	5	20.0	10	20.0	5	20.0	5	20.9	10	20.0	5	20.0	2	20.0	
		(20.00,		(20.00,		(20.00,		(18.48,		(20.00,		(20.00,		(NA)	
		20.00)		20.00)		20.00)		23.67)		20.00)		20.00)			
Luminex anti-S															
IgM															
Day 1	5	50.0	10	73.5	5	84.7	5	77.9	10	67.3	5	53.0	2	73.1	
		(50.00,		(50.77,		(44.63,		(34.93,		(47.40,		(45.06,		(NA)	
		50.00)		106.51)		160.91)		173.82)		95.49)		62.37)			
Day 8	5	53.5	10	73.6	5	63.9	5	140.1	10	63.3	5	56.1	2	116.4	
		(44.37,		(53.95,		(42.06,		(11.23,		(46.52,		(40.74,		(NA)	
		64.47)		100.50)		97.20)		1749.25)		86.06)		77.29)			

	Age 21 – 55										Age 56 – 80			0
		1 µg		5 µg		7.5 μg		10.0 µg	Poo	led Placebo		7.5 μg	C	ohort D2
	(C	ohort A)	(0	Cohort B)	(C	ohort D1)	(0	Cohort C)	(Co	ohorts A, B,	(C	ohort D2)	Placebo	
		N=5		N=10	N=5			N=5		C, D1)		N=5	N=2	
										N=10				
Test/Time point	n	GMT	No	GMT	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT
		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)
Day 15	5	90.6	10	427.0	5	215.4	5	646.9	10	60.8	5	171.1	2	136.4
		(28.15,		(141.33,		(104.49,		(99.38,		(42.94,		(69.58,		(NA)
		291.26)		1290.32)		443.91)		4211.00)		86.03)		420.93)		
Luminex anti-S														
IgA														
Day 1	5	383.1	10	142.1	5	101.1	5	236.1	10	111.7	5	61.5	2	88.3
		(36.21,		(56.96,		(52.46,		(73.94,		(86.18,		(44.63,		(NA)
		4052.75)		354.28)		194.97)		754.10)		144.75)		84.76)		
Day 29	5	2119.1	10	1259.6	5	525.3	5	9056.6	10	84.9	5	321.7	2	162.9
		(159.82,		(336.74,		(159.82,		(1083.57,		(64.26,		(88.20,		(NA)
		28096.25)		4711.46)		1726.38)		75696.55)		112.21)		1172.99)		
T														
Luminex anti-														
RBD IgG*														

					A	ge 21 – 55						Age 5	6 – 8	0
		1 µg		5 µg		7.5 μg		10.0 µg	Poo	led Placebo		7.5 μg	C	ohort D2
	(C	cohort A)	(0	Cohort B)	(C	ohort D1)	(C	Cohort C)	(Co	ohorts A, B,	(C	ohort D2)]	Placebo
		N=5		N=10		N=5		N=5		C, D1)		N=5		N=2
										N=10				
Test/Time point	n	GMT	No	GMT	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT
		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)
				574		631				513		510		926
			10	(467;	5	(411;			6	(340;	5	(369;	2	(8;
Day 1				707)		969)				774)		705)		113760)
				2618		3578				653		1665		1113
Day 29			10	(1299;	5	(1171;			6	(389;	5	(717;	2	(52;
				5276)		10932)				1098)		3869)		23697)
Luminex anti-														
NTD IgG*														
				276		269				308		269		347
Day 1			10	(242;	5	(223;			6	(198;	5	(202;	2	(61;
				314)		326)				481)		357)		1964)
				443		446				323		420		309
Day 29			10	(359;	5	(260;			6	(220;	5	(290;	2	(174;
				548)		766)				474)		608)		549)

					A	ge 21 – 55						Age 50	5 – 8	0
		1 µg		5 µg		7.5 μg		10.0 µg	Poo	led Placebo		7.5 μg	C	ohort D2
	(C	Cohort A)	(C	ohort B)	(C	ohort D1)	(0	Cohort C)	(Co	ohorts A, B,	(C	ohort D2)	1	Placebo
		N=5		N=10		N=5		N=5		C, D1)		N=5		N=2
										N=10				
Test/Time point	n	GMT	No	GMT	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT
		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)
Luminex anti-S2														
IgG*														
			10	305	5	204			6	390		192	2	276
				(156;		(149;				(144;		(116;		(215;
Day 1				596)		279)				1055)		317)		356)
				9703		55676				380		6520		270
Day 29			10	(3631;	5	(18159;			6	(152;		(506;	2	(101;
				25928)	5 (18159; 170702)					953)		83940)		725)

S = Full-Length SARS-CoV-2 Spike Protein; S2 = S2 domain of SARS-CoV-2 Spike Protein, RBD = receptor binding domain of SARS-CoV-2 Spike Protein; NTD =N-terminal domain of SARS-CoV-2 Spike Protein; PRNT =Plaque Reduction Neutralization Test; GMT=Geometric Mean Titer; CI=Confidence Interval;

N represents the total number of subjects in each cohort. n represents the number of subjects contributing to the summary.

*IgG titers against RBD, NTD and S2 not assessed for subjects in Cohorts A and C.

Table S6. Antibody responses in 2-Dose Cohorts

			Ag	ge 21 – 55					A	ge 56 – 80		
Test/Time point	((3 μg Cohort F)	(0	5 μg Cohort E)	Ed	Cohorts & F Pooled	(3 µg Cohort H)	(0	5 μg Cohort G)	Ge	Cohorts &H Pooled
		N=12		N=12		Placebo		N=12		N=12]	Placebo
						N=8						N=8
	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT
		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)
Luminex anti-S												
IgG												
Day 1	12	261.9	12	321.8	8	251.8	12	410.2	12	334.4	8	421.2
		(170.17,		(244.70,		(140.56,		(221.33,		(218.67,		(286.14,
		403.15)		423.10)		451.18)		760.35)		511.27)		620.11)
Day 15	12	1894.6	12	1836.6	8	201.0	12	947.0	12	1423.6	8	339.2
		(511.61,		(1032.43,		(71.11,		(342.52,		(573.93,		(162.05,
		7016.17)		3267.05)		568.04)		2618.17)		3531.12)		710.14)
Day 29	12	5507.2	12	5614.9	8	299.1	12	2450.7	12	8407.0	8	266.2
		(1782.55,		(3669.54,		(160.18,		(750.65,		(3437.58,		(135.63,
		17014.70)		8591.57)		558.63)		8000.85)		20560.50)		522.46)
Day 36	12	5677.3	12	7130.1	8	215.2	12	2971.1	12	7583.3	8	381.6
		(1683.63,		(4294.36,		(81.58,		(923.92,		(3348.57,		(216.40,
		19144.15)		11838.49)		567.53)		9554.20)		17173.44)		672.96)

			Ag	ge 21 – 55					A	ge 56 – 80		
Test/Time point		3 µg		5 µg		Cohorts		3 µg		5 µg	(Cohorts
	((Cohort F)	(0	Cohort E)	Еð	& F Pooled	(Cohort H)	((Cohort G)	Gð	&H Pooled
		N=12		N=12		Placebo		N=12		N=12]	Placebo
						N=8						N=8
	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT
		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)
Day 43	12	14481.0	12	16771.9	8	232.4	12	5085.5	12	16513.5	8	335.8
		(6079.57,		(10507.27		(109.91,		(1348.87,		(7432.56,		(128.80,
		34492.51)		,		491.39)		19173.26)		36689.28)		875.63)
				26771.56)								
Day 57	12	13079.9	12	16558.1	8	360.0	12	5903.9	12	10375.4	8	386.4
		(5068.41,		(9486.89,		(189.44,		(1967.62,		(5580.18,		(200.55,
		33755.04)		28899.99)		684.30)		17714.81)		19291.17)		744.63)
Day 85	12	9526.0	12	11592.6	8	265.9	12	5463.5	12	11998.1	8	421.1
		(4090.22,		(6630.05,		(113.09,		(2085.67,		(5247.08,		(205.39,
		22185.61)		20269.63)		625.08)		14312.11)		27435.30)		863.45)

			Ag	ge 21 – 55					Aş	ge 56 – 80		
Test/Time point		3 µg		5 µg	(Cohorts		3 μg		5 µg		Cohorts
	(0	Cohort F)	(0	Cohort E)	Εð	& F Pooled	(Cohort H)	(0	Cohort G)	Gð	&H Pooled
		N=12		N=12		Placebo		N=12		N=12]	Placebo
						N=8						N=8
	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT
		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)
Live Virus												
PRNT ₅₀												
Day 1	12	20.0	12	20.0	8	20.0	12	20.0	12	20.0	8	20.0
		(20.00,		(20.00,		(20.00,		(20.00,		(20.00,		(20.00,
		20.00)		20.00)		20.00)		20.00)		20.00)		20.00)
Day 29	12	27.3	12	29.3	8	20.0	12	22.5	12	20.6	8	20.0
		17.41,		(23.09,		(20.00,		(19.47,		(19.34,		(20.00,
		42.84)		37.13)		20.00)		26.10)		21.88)		20.00)
Day 43	12	34.9	12	51.8	8	20.0	12	27.1	12	24.0	8	20.0
		(24.14,		(32.30,		(20.00,		(15.17,		(20.56,		(20.00,
		50.38)		83.21)		20.00)		48.35)		27.95)		20.00)
Day 57	12	23.8	12	36.0	8	20.0	12	29.7	12	20.4	8	20.0
		(17.39,		(24.32,		(20.00,		(15.63,		(19.71,		(20.00,
		32.47)		53.16)		20.00)		56.37)		21.09)		20.00)

			Ag	ge 21 – 55					A	ge 56 – 80		
Test/Time point		3 µg		5 µg	(Cohorts		3 µg		5 µg	(Cohorts
	((Cohort F)	(0	Cohort E)	Еð	& F Pooled	(Cohort H)	(0	Cohort G)	Gð	&H Pooled
		N=12		N=12		Placebo		N=12		N=12		Placebo
						N=8						N=8
	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT
		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)
Day 85	11	24.4	12	25.0	8	20.0	11	27.0	12	20.0	8	20.0
		(17.88,		(18.94,		(20.00,		(16.51,		(20.00,		(20.00,
		33.30)		33.06)		20.00)		44.13)		20.00)		20.00)
Luminex anti-S												
IgM												
_	12	61.5	12	62.6	8	71.8	12	83.1	12	62.7	8	59.2
Day 1		(42.99,		(50.74,		(52.43,		(60.16,		(47.16,		(42.82,
		88.04)		77.19)		98.23)		114.66)		83.40)		81.82)
	12	222.7	12	194.5	8	60.7	12	145.1	12	114.1	8	54.3
Day 15		(108.47,		(128.76,		(38.50,		(64.55,		(65.55,		(45.75,
		457.22)		293.83)		95.81)		326.32)		198.53)		64.53)

			Ag	ge 21 – 55					Aş	ge 56 – 80		
Test/Time point		3 µg		5 µg	(Cohorts		3 µg		5 µg		Cohorts
	((Cohort F)	(C	cohort E)	Еð	& F Pooled	(Cohort H)	(0	Cohort G)	Gð	&H Pooled
		N=12		N=12		Placebo		N=12		N=12]	Placebo
						N=8						N=8
	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT
		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)
Luminex anti-S												
IgA												
	12	149.2	12	107.1	8	164.9	12	182.4	12	127.7	8	225.2
Day 1		(111.02,		(79.89,		(119.89,		(93.43,		(99.85,		(157.52,
		200.55)		143.45)		226.68)		356.08)		163.38)		322.02)
	12	704.6	12	413.6	8	186.4	12	853.5	12	619.8	8	174.0
Day 29		(445.38,		(255.87,		(129.55,		(278.06,		(186.82,		(85.99,
		1114.72)		668.45)		268.28)		2619.52)		2056.61)		352.00)
	12	519.8	12	631.8	8	121.6	12	1034.3	12	1174.9	8	250.5
Day 57		(306.07,		(364.71,		(86.83,		(325.44,		(341.39,		(137.70,
		882.76)		1094.58)		170.31)		3287.32)		4043.68)		455.66)

			Ag	ge 21 – 55					A	ge 56 – 80		
Test/Time point	(0	3 μg Cohort F)	(0	5 μg Cohort E)	Eð	Cohorts & F Pooled	()	3 μg Cohort H)	(0	5 μg Cohort G)	G	Cohorts &H Pooled
		N=12		N=12		Placebo N=8		N=12		N=12]	Placebo N=8
	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)	n	GMT (95% CI)
Luminex anti-												
RBD IgG*												
			12	648	4	731			12	506	4	580
Day 1				(480,		(329,				(430,		(417,
				876)		1624)				596)		806)
			12	1606	4	672			12	1048	4	649
Day 29				(1227,		(632,				(696,		(378,
				2103)		714)				1579)		1114)
			12	4211	4	505			12	3190	4	798
Day 57				(2665,		(402,				(1744,		(553,
				6656)		634)				5833)		1151)

			Ag	ge 21 – 55					Ag	ge 56 – 80		
Test/Time point		3 µg		5 µg	(Cohorts		3 µg		5 µg		Cohorts
	((Cohort F)	(C	Cohort E)	Еð	& F Pooled	(Cohort H)	(0	Cohort G)	Gð	&H Pooled
		N=12		N=12		Placebo		N=12		N=12]	Placebo
						N=8						N=8
	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT
		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)
Luminex anti-												
NTD IgG*												
				466		600				468		519
Day 1			12	(296,	4	(211,			12	(377,	4	(260,
				731)		1709)				581)		1034)
				862		643				569		567
Day 29			12	(746,	4	(611,			12	(441,	4	(353,
				995)		676)				734)		913)
				1169		505				1083		747
Day 57			12	(923,	4	(416,			12	(781,	4	(497,
				1479)		614)				1502)		1124)

			Ag	ge 21 – 55					A	ge 56 – 80		
Test/Time point		3 µg		5 µg	(Cohorts		3 μg		5 µg		Cohorts
	(0	Cohort F)	(C	cohort E)	Еð	& F Pooled	(Cohort H)	(0	Cohort G)	Gð	&H Pooled
		N=12		N=12		Placebo		N=12		N=12]	Placebo
						N=8						N=8
	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT	n	GMT
		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)
Luminex anti-S2												
IgG*												
Day 1				590		1255				503		486
			12	(334,	4	(937,			12	(374,	4	(234,
				1045)		1681)				678)		1010)
Day 29				9262		1238				10133		546
			12	(5455,	4	(447,			12	(5034,	4	(410,
				15724)		3430)				20396)		726)
Day 57				15272		1049				22794		798
			12	(7489,	4	(361,			12	(13235,	4	(675,
				31144)		3045)				39258)		944)

S = Full-Length SARS-CoV-2 Spike Protein; S2 = S2 domain of SARS-CoV-2 Spike Protein, RBD = receptor binding domain of SARS-CoV-2 Spike Protein; NTD =N-terminal domain of SARS-CoV-2 Spike Protein; PRNT =Plaque Reduction Neutralization Test; GMT=Geometric Mean Titer; CI=Confidence Interval;

			Ag	ge 21 – 55					A	ge 56 – 80		
Test/Time point		3 µg		5 µg		Cohorts		3 µg		5 µg		Cohorts
	(Cohort F)		(0	Cohort E)	Еð	& F Pooled	(Cohort H)	(0	Cohort G)	Gð	&H Pooled
	N=12			N=12		Placebo		N=12		N=12]	Placebo
						N=8						N=8
	n	n GMT		GMT	n	GMT	n	GMT	n	GMT	n	GMT
		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)		(95% CI)

N represents the total number of subjects in each cohort. n represents the number of subjects contributing to the summary.

*IgG titers against RBD, NTD and S2 were not assessed for subjects in cohorts F and H.



Figure S1. Spike location of the peptide pools used in the cellular assays.



A. YA cohorts (21-55 yrs)



ELISPOT results on study days 1, 15, 29 and/or 57 are presented as spot forming cells (SFC) per 10⁶ PBMCs are displayed for single dose cohorts of younger adults (YA) (Panel A) and older adults (OA) (Panel B). Note that day 29 data is only for Cohorts A and B. Bar graphs display data as mean per group with error bars depicting the standard deviation (SD). Each dot represents an individual participant.



Figure S3. ELISPOT responses by tested peptide pool in 2 dose cohorts.

ELISPOT results are presented as spot forming cells (SFC) per 10⁶ PBMCs are displayed for two-dose cohorts of younger adults (YA) (Panel A) and older adults (OA) (Panel B). Bar graphs display data as mean per group with error bars depicting the standard deviation (SD). Each dot represents and individual participant.

A) One-Dose Cohorts



Figure S4. Antigen-specific IFN_γ CD8 T cell responses by ICS.

Total antigen-specific IFNγ responses in CD8 T cells following stimulation with Spike peptide pools are presented for one-dose (Panel A) and two-dose (Panel B) cohorts. Horizontal bar displays mean per group with error bars depicting the standard deviation (SD). Each dot represents and individual participant. Younger adults 21-55 years; older adults 56-80 years.

A) One-Dose Cohorts



Figure S5. Antigen-specific IFN_γ CD4 T cell responses by ICS.

Total antigen-specific IFNγ responses in CD4 T cells following stimulation with Spike peptide pools are presented for one-dose (Panel A) and two-dose (Panel B) cohorts. Horizontal bar displays mean per group with error bars depicting the standard deviation (SD). Each dot represents and individual participant. Younger adults 21-55 years; older adults 56-80 years.

A) One-Dose Cohorts



B) <u>Two-Dose Cohorts</u>



Figure S6. Antigen-specific IFNy and IL4 CD4 T cell responses by ICS.

Total antigen-specific IFN γ and IL4 responses in CD4 T cells following stimulation with Spike peptide pools were measured to assess Th1 responses. Figure presents data for one-dose (Panel A) and two-dose (Panel B) cohorts. Horizontal bar displays mean per group with error bars depicting the standard deviation (SD). Each dot represents and individual participant. Younger adults 21-55 years; older adults 56-80 years.